Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.60 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.47 |
| ▸ | CALCA | P06881 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198319 | 1.00 | CALCRL (0.60) | CALCRLRAMP1CALCA | |
| SCHEMBL3066255 | 1.00 | CALCRL (0.60) | CALCRLRAMP1CALCA | |
| SCHEMBL13050655 | 1.00 | CALCRL (0.60) | CALCRLRAMP1CALCA | |
| SCHEMBL13036911 | 1.00 | CALCRL (0.60) | CALCRLRAMP1CALCA | |
| Hydrochloric Acid SCHEMBL4663029 | 0.99 | CALCRL (0.59) | CALCRLRAMP1CALCA | |
| Hydrochloric Acid SCHEMBL3058435 | 0.99 | CALCRL (0.59) | CALCRLRAMP1CALCA | |
| SCHEMBL4570460 | 0.89 | CALCRL (0.53) | CALCRLRAMP1CALCA | |
| Hydrochloric Acid SCHEMBL3711079 | 0.88 | CALCRL (0.52) | CALCRLRAMP1CALCA | |
| SCHEMBL1198159 | 0.87 | CALCRL (0.50) | CALCRLRAMP1CALCA | |
| SCHEMBL5134420 | 0.87 | CALCRL (0.50) | CALCRLRAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007731-A2 | PROCESS FOR THE PREPARATION OF CAPROLACTAM CGRP ANTAGONIST INTERMEDIATE | Merck & Co., Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007120589-A2 | PROCESS FOR THE PREPARATION OF CAPROLACTAM CGRP ANTAGONIST INTERMEDIATE | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | claimed |
| US-20090176986-A1 | Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate | MERCK SHARP & DOHME CORP. | 2009-07-09 | — | — | US | disclosed |
| EP-2007395-A1 | CGRP ANTAGONIST SALT | Merck & Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-2007731-A2 | PROCESS FOR THE PREPARATION OF CAPROLACTAM CGRP ANTAGONIST INTERMEDIATE | Merck & Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-2007764-A1 | PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST | Merck & Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007120589-A2 | PROCESS FOR THE PREPARATION OF CAPROLACTAM CGRP ANTAGONIST INTERMEDIATE | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120592-A1 | CGRP ANTAGONIST SALT | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120591-A1 | PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1799672-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7235545-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2006041830-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1638969-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005072308-A9 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050256098-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2005-11-17 | — | — | US | disclosed |
| WO-2004092166-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176986-A1 | Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate | CCKBR, CALCRL, CALCR | CALCRL 2/4885RAMP1 67/4885CALCA 6/4885 |
| US-20050256098-A1 | CGRP receptor antagonists | CCKBR, BDKRB1, BDKRB2 | CALCRL 6/4885RAMP1 187/4885CALCA 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.